MedWatch

Novo Holdings board member steps down after less than two years in role

Carsten Stendevad has chosen to leave Novo Holdings' board as he has been given new investment responsibilities at the world's largest hedge fund, Bridgewater.

Carsten Stendevad | Photo: PR/ Bridgewater Associates

After just under two years in the role of board member at Novo Nordisk fund Novo Holdings, Carsten Stendevad has chosen to step down.

Novo Holdings reports that this is due to the fact that he has been given new investment responsibilities connected to his role of co-CIO for sustainability at the world's largest hedge fund, Bridgewater. Stendevad was voted onto the Novo Holdings board in March 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs